钇-90经动脉放射性栓塞治疗肝细胞癌的远期临床结局:一家机构5年经验
该回顾性研究评估了2017至2021年一家学术医学中心88例原发肝细胞癌患者接受钇-90经动脉放射性栓塞治疗的临床结局。平均给药剂量127.8±20.2 Gy,6个月影像学客观缓解率83.3%,中位无进展生存期9.6±8.5个月,平均生存期14.7±12.1个月;6个月时77.3%的患者维持或降期至米兰标准,1年和2年分别为74.4%和70.0%。作者认为钇-90经动脉放射性栓塞是安全有效的治疗,持久结局可作为肝移植的现实桥接。
要点
- 6个月影像学客观缓解率达83.3%,平均无进展生存期9.6±8.5个月。
- 6个月时77.3%患者维持或降期至米兰标准,1年及2年分别为74.4%和70.0%。
- 治疗后无显著并发症或肝功能检查升高,平均生存期14.7±12.1个月。
核心结论
- 钇-90经动脉放射性栓塞是原发肝细胞癌安全有效的治疗,持久结局可作为肝移植的现实桥接,多数患者长期维持米兰标准并保留功能状态。
研究设计与样本
- 回顾性研究,纳入2017至2021年一家学术医学中心88例连续接受钇-90经动脉放射性栓塞治疗的原发肝细胞癌患者。
关键影像表现/征象
- 双叶分布占60.2%,平均病灶直径5.0±3.4 cm,巴塞罗那临床肝癌分期B或C期占77%。
- 平均给药钇-90辐射剂量127.8±20.2 Gy。
诊断标准与关键数值
- 6个月影像学客观缓解率为83.3%,平均无进展生存期为9.6±8.5个月。
- 73.9%的患者为甲胎蛋白阳性肿瘤,其中67.8%在治疗后1个月出现完全或部分生化缓解。
- 治疗后6个月77.3%的患者降期至或维持米兰标准,1年及2年分别为74.4%和70.0%。
- 东部肿瘤协作组功能状态在治疗后6个月和1年分别有79.6%和76.1%的患者维持或改善。
临床应用与阅片要点
- 作者认为钇-90经动脉放射性栓塞是原发肝细胞癌安全有效的治疗,持久结局可作为肝移植的现实桥接。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To examine the clinical outcomes of yttrium-90 (Y90) transarterial radioembolization (TARE) for primary hepatocellular carcinoma (HCC) through the evaluation of a 5-year institutional experience.
MATERIALS AND METHODS: This retrospective study evaluated 88 consecutive patients with primary HCC receiving Y90 TARE treatment at an academic medical center from 2017 to 2021. Disease distribution was bilobar in 60.2% of patients with an average lesion diameter of 5.0 ± 3.4 cm and Barcelona Clinic Liver Cancer stage B or C in 77% of the participants. Clinical outcomes were elucidated by examination of complications, liver function tests, biochemical response, and radiographic response. Objective response ratio (ORR) and progression-free survival (PFS) were also calculated.
RESULTS: The mean administered Y90 radiation dose was 127.8 ± 20.2 Gy. No significant complications or LFT elevations occurred post-therapy. Of the 73.9% of patients with α-fetoprotein-producing tumors, 67.8% experienced a complete or partial biochemical response 1 month post-treatment. The ORR was 83.3% on 6-month imaging and PFS was 9.6 ± 8.5 months. Functional outcomes (Eastern Cooperative Oncology Group) were maintained or improved in 79.6% and 76.1% of patients by 6 months and 1 year post-treatment, respectively. The mean survival was 14.7 ± 12.1 months. At 6 months post-treatment, 77.3% of patients were downstaged to or maintained Milan criteria, which was sustained for 74.4% and 70.0% of patients 1 year and 2 years after treatment, respectively.
CONCLUSION: Y90-TARE is a safe and effective therapy for primary HCC. Enduring outcomes further act as a realistic bridge to liver transplantation, with a majority of patients maintaining Milan criteria and preserving their functional status long term.
引用
- Makary MS, Bozer J, Miller ED, et al. Long-term Clinical Outcomes of Yttrium-90 Transarterial Radioembolization for Hepatocellular Carcinoma: A 5-Year Institutional Experience. Acad Radiol. 2023. PMID: 37537129. doi:10.1016/j.acra.2023.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。